Humatrope for short stature
Executive Summary
Lilly's growth hormone Humatrope (somatropin, rDNA origin) approved by FDA for idiopathic short stature July 25. Lilly will not conduct DTC advertising for Humatrope, will market the new indication only to pediatric endocrinologists and will distribute the product through controlled channels, as discussed during FDA's Endocrinologic & Metabolic Drugs Advisory Committee's June 10 review (1"The Pink Sheet" June 16, 2003, p. 28)...
You may also be interested in...
Lilly Humatrope Postmarket Plans: Voluntary Study, No Patient Registry
An assessment of the long-term safety and efficacy of Lilly's Humatrope for idiopathic short stature will rely on a voluntary ongoing postmarket research program
Lilly Humatrope Risk Plan Relies On Limited Promos; Cmte. Wants Registry
Lilly's proposed risk management program for use of Humatrope in non-growth hormone deficient short stature includes an effort to carefully tailor promotions for the pending supplemental indication
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.